Company intelligence / Profile preview

Gila Therapeutics

Boston, Massachusetts, United Statesgilatherapeutics.com ↗

Ownership: Private
Employees: ~10
Development stage: Phase 1

Overview

Completed a successful Phase I trial for Topical Lingual PYY which showed strong efficacy with zero treatment-related adverse events or serious adverse events

Therapeutic areas: EndocrinologyMetabolic Disorders
Modalities: PeptidesRecombinant polypeptideSynthetic peptide
Industry: Biotech

Drug pipeline

4 assets

peptide YY 3-36

3 more assets in the full pipeline.

Request access →

Partnerships

Pharmaceutical, biotech, and consumer health companies (unnamed)Research universities (unnamed)

Beyond the preview

Go deeper on Gila Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Gila Therapeutics.

Explore the full profile